← All protocolsProtocol card Constituent peptides Supply provenance
Citations
Grade BRUOverifiedBioGate · GREEN
Dermal & Follicular Renewal
Photoaged skin, scalp follicle restoration in androgenic-alopecia early stage
Eight audiences, one source of truth.
For clinicians
Dose & cycle
GHK-Cu 1% topical bid + microneedling 1.5 mm weekly
Cycle
Continuous topical
Duration
16 weeks, photographic + trichoscopy at week 0 / 8 / 16
For patients
Monitoring endpoints
- ✓modified Hamilton-Norwood
- ✓trichoscopy follicular density
- ✓VISIA wrinkle score
Contraindications
- ✕copper allergy
- ✕active dermatitis at site
Jurisdiction gates
US ✓
Cosmetic, non-prescription
EU ✓
Cosmetic regulation 1223/2009
UK ✓
Cosmetic
AU ✓
Cosmetic
Provenance, attestations, and structures.
GHK-CuverifiedBioGate · GREEN
Structural preview · ESMFold-2 mockdeterministic per sequence
GHKTripeptide-copper complex; modulates gene expression in dermal fibroblasts and downregulates TGF-β scarring pathways.
IP economics
Cohort outcomes feed the royalty cascade.
Every revealed OEA from this protocol's cohorts updates the upstream IPNFT's outcome posterior. Holders receive pro-rata royalties from licensing, lab-fee escrow, and approved CRO contracts. Peptide MD does not custody the IPNFT; it indexes it through the Molecule registry.
IPNFT · Molecule IPNFT V2Solana
GHK-Cu
bb9aee…94c09aRoyalty cascade
8.07%
Holders
323
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
COA-backed batches in the index.
| Batch | Supplier | Purity (HPLC) | Endotoxin (EU/mg) | Manufactured | Hash |
|---|---|---|---|---|---|
| HP-GHK-2026-0228-B | Helix Pharma EU Netherlands (GMP Annex 1) | 98.9% | 0.18 | 2026-02-28 |
Every claim, traceable.
Grade A2018 · Int J Mol Sci
The Effect of the Human Peptide GHK on Gene Expression Relevant to Skin
Pickart L, Margolina A.